endovascular angioplasty using covered stents
ProcedurePrimary endovascular angioplasty using one or several covered stents
NCT Number: NCT03586739
Chronic Mesenteric Ischemia (CMI) is defined by one or more arterial digestive lesions, responsible for severe mesenteric symptoms. The clinical presentation of CMI is characterized by postprandial abdominal pain and weight loss, leading to severe malnutrition. It is a frequent pathology which affects preferentially the elderly patients of female sex (70%) with cardio-vascular comorbidities. Risk factors include smoking, hypertension, and dyslipidemia.
Despite medical and diagnostic advances, the morbidity and mortality of CMI remain very high (>70%). Optimal management of CMI is based on early diagnosis. Symptomatic patients with CMI should be treated without much delay to relief symptoms (present in 43% patients) and prevent acute mesenteric ischemia.
The three visceral arteries affected by atherosclerotic disease are coeliac trunc, inferior mesenteric artery and Superior Mesenteric Artery (SMA). The SMA is treated the most frequently, because it is the main relevant artery associated with CMI.
Endovascular treatment (angioplasty and stenting) is considered as the first-line treatment for CMI when feasible. It is indicated especially in the case of high grade stenosis or occlusion of the Superior Mesenteric Artery. Two types of stents can be used for this procedure: bare metal stents (BMS) or covered stents (CS).
Even if BMS are standard care there is no consensus on the type of stent to use.
There are very few reported series with large numbers of patients comparing BMS and CS in this indication. However, to our knowledge, no results from a randomized study addressing this issue have ever been published. These are only retrospective with a low level of evidence (IIb). The largest series compared 147 patients with primary intervention for CMI treatment using BMS versus 42 using CS. Treatment with CS showed better results in terms of symptom recurrence (10% vs 32%, p <0.002), restenosis (12% vs 42%, p <0.0002) and re-interventions (10% vs 42%), after at least 1 year of follow-up. Indeed, endovascular treatment using BMS was associated with high incidence of symptoms recurrence despite the satisfying patency rates in both occluded and stenotic vessels.
There are no international guidelines to recommend the use of one or another sort of stent.
The necessity of a randomised study addressing the issue of bare metal versus covered stents deployment seems to be important.
The investigators propose to demonstrate that covered stents presents a better efficacy than bare metal stents, with a multicenter randomized study involving 24 vascular surgical departments of French University Hospitals.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Département de Chirurgie Vasculaire, CHU d'Angers, Angers, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Primary endovascular angioplasty using one or several covered stents
Primary endovascular angioplasty using one or several bare metal stents
a Duplex-scan will be performed during patient follow up.
a CT-scan will be performed in the event of symptoms of recurrence or restenosis as confirmatory exam according to clinical practice during patient follow up.
The CT-scan will be mandatory at 12 and 24 months if it has not been planned in the current practice follow-up.
In case CT-scan cannot be performed (e.g. occurrence of a non-preexisting contra-indication), a digital angiography will be authorised instead to confirm restenosis during patient follow-up.
The patient will complete a quality-of-life questionnaire (SF-36 form) during their follow up.
Time frame: 24 months after the primary endovascular treatment
Freedom from restenosis will be defined as ≥50% luminal reduction and/or thrombosis, confirmed by CT-scan.
The crude percentage of restenosis and/or thrombosis at 24 months will be computed for each group. The survival curves for freedom from restenosis and/or thrombosis will be plotted according to the Kaplan-Meier method and overall survival rates will be estimated.
Time frame: up to discharge from hospital
Time frame: 24 months after the primary endovascular treatment
Time frame: 6 months after the primary endovascular treatment
Time frame: 12 months after the primary endovascular treatment
Time frame: 18 months after the primary endovascular treatment
Time frame: 24 months after the primary endovascular treatment
Repeat revascularisation for a lesion anywhere within the primary stent or the 5-mm borders proximal or distal to the stent
Time frame: 24 months after the primary endovascular treatment
Clinical recurrence, defined as the symptomatic recurrence of chronic, subacute or acute mesenteric ischemia
Time frame: 24 months after the primary endovascular treatment
Time frame: 24 months after the primary endovascular treatment
Occurrence of major morbidity and description of the events
Time frame: 24 months after the primary endovascular treatment
quality of life will be compared between the two groups and assessed using the SF-36 questionnaire
Time frame: at inclusion
quality of life will be compared between the two groups and assessed using the SF-36 questionnaire
Time frame: 6 months after the primary endovascular treatment
quality of life will be compared between the two groups and assessed using the SF-36 questionnaire
Time frame: 12 months after the primary endovascular treatment
quality of life will be compared between the two groups and assessed using the SF-36 questionnaire
Time frame: 12 months after the primary endovascular treatment
The freedom from restenosis will be defined as ≥50% luminal reduction and/or thrombosis, confirmed by CT-scan.
The crude percentage of restenosis and/or thrombosis at 12 months will be computed for each group. The survival curves for freedom from restenosis and/or thrombosis will be plotted according to the Kaplan-Meier method and overall survival rates will be estimated.
Hospices Civils de Lyon
Other
Evaluation of Covered Stents Versus Bare Metal Stents for Endovascular Treatment of Chronic Atherosclerotic Mesenteric Arterial Disease:a Randomised Study.
Acronym: ESTIMEC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06022588
Chronic Mesenteric Ischemia, Disease
Rotterdam, Netherlands
View Trial DetailsNCT02914912
Chronic Mesenteric Ischemia
Oslo, Norway
View Trial DetailsNCT07182669
Chronic Mesenteric Ischemia
Copenhagen, State, Denmark
View Trial DetailsNCT07059520
Cardiovascular Diseases, Chronic Mesenteric Ischemia
Enschede, Overijssel, Netherlands
View Trial Details